Use of antipsychotics in children and adolescents

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 7, 2005, Pages 29-40

  Findling, Robert L ^a   Steiner, Hans ^b   Weller, Elizabeth B ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; BENZATROPINE; BIPERIDEN; CHOLESTEROL; CLOZAPINE; HALOPERIDOL; LITHIUM; LOXAPINE; METHYLPHENIDATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; VALPROIC ACID; ZIPRASIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGGRESSION; AGITATION; AGRANULOCYTOSIS; AKATHISIA; AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ANXIETY DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; CONDUCT DISORDER; CONFERENCE PAPER; DELIRIUM; DEPRESSION; DEVELOPMENTAL DISORDER; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; DYSPHORIA; DYSTONIA; EATING DISORDER; EEG ABNORMALITY; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; INTELLIGENCE; LEUKEMIA; LEUKOPENIA; MALADJUSTMENT; MANIA; MOTOR DYSFUNCTION; NEUTROPENIA; OROFACIAL DYSKINESIA; PARKINSONISM; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; QT PROLONGATION; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STANDING; STUPOR; TACHYCARDIA; TARDIVE DYSKINESIA; TIC; TITRIMETRY; TREMOR; VISUAL IMPAIRMENT; WEIGHT GAIN;

ADOLESCENT; AGE FACTORS; AGGRESSION; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIPOLAR DISORDER; CHILD; CHILD BEHAVIOR DISORDERS; DEVELOPMENTAL DISABILITIES; HUMANS; HYPERPROLACTINEMIA; MENTAL DISORDERS; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 25144437833     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (150)

1. Zito JM, Craig TJ, Wanderling J. Pharmacoepidemiology of 300 child/adolescent psychiatric patients. J Pharmacoepidemiol 1994;3:47-62
2. Findling RL. Dosing of atypical antipsychotics in children and adolescents. J Clin Psychiatry 2003;5(suppl 6):10-13
3. Asarnow JR, Tompson MC, Goldstein MJ. Childhood-onset schizophrenia: a followup study. Schizophr Bull 1994;20:599-617
4. Eggers C, Bunk D. The long-term course of childhood-onset schizophrenia: a 42-year followup. Schizophr Bull 1997;23:105-117
5. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-897
6. McLellan J, Werry J. Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1997;36(suppl 10):177S-193S
7. Remschmidt HE, Schulz E, Martin M, et al. Childhood-onset schizophrenia: history of the concept and recent studies. Schizophr Bull 1994;20: 727-745
8. Spencer EK, Campbell M. Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy. Schizophr Bull 1994;30:713-725
9. Meltzer HY, Rabinowitz J, Lee MA, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997;154:475-482
10. Findling RL, McNamara NK, Gracious BL. Paediatric uses of atypical antipsychotics. Expert Opin Pharmacother 2000;1:935-945
11. Findling RL, Friedman L, Kenny JT, et al. Adolescent schizophrenia: a methodologic review of the current neuroimaging and neuropsychologic literature. J Autism Dev Disord 1995;25:627-639
12. Kutcher SP. Child and Adolescent Psychopharmacology. Philadelphia, Pa: WB Saunders Company; 1997
13. Stayer C, Sporn A, Gogtay N, et al. Looking for childhood schizophrenia: case series of false positives. J Am Acad Child Adolesc Psychiatry 2004; 43:1026-1029
14. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2001;40 (suppl 7):4S-23S
15. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004;65(suppl 6):30-44
16. Malone RP, Sheikh R, Zito JM. Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 1999;50:171-174
17. Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry 1998;59:644-656
18. Pool D, Bloom W, Mielke DH, et al. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 1976;19:99-104
19. Realmuto GM, Erickson WD, Yellin AM, et al. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 1984;141:440-442
20. Conley RR, Kelly DL. Current status of antipsychotic treatment. Curr Drug Targets CNS Neurol Disord 2002;1:123-128
21. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-1097
22. Frazier JA, Gordon CT, McKenna K, et al. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994;33:658-663
23. Turetz M, Mozes T, Toren P, et al. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry 1997;170:507-510
24. Remschmidt H, Schulz E, Martin PDM. An open trial of clozapine in thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 1994;4:31-41
25. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29:133-145
26. Armenteros JL, Whitaker AH, Welikson M, et al. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 1997;36:694-700
27. Gothelf D, Apter A, Reidman J, et al. Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 2003;110:545-560
28. Zalsman G, Carmon E, Martin A, et al. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 2003;13:319-327
29. Kumra S, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998;37:377-385
30. Mandoki M. Olanzapine in the treatment of early onset schizophrenia in children and adolescents [abstract 71]. Biol Psychiatry. 1997;41:22S
31. Findling RL, McNamara NK, Youngstrom EA, et al. A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2003;42:170-175
32. Ross RG, Novins D, Parley GK, et al. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 2003;13:301-309
33. McConville B, Carrero L, Sweitzer D, et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 2003;13:75-82
34. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000;61:252-260
35. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001;11:415-424
36. Kane JM. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J Clin Psychiatry 2003;64(suppl 19):19-25
37. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizo-affective disorder. J Clin Psychiatry 2002;63:763-771
38. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690
39. Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003;17:423-430
40. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389
41. Shapiro DA, Renock S, Arlington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411
42. Geller B, Zimerman B, Williams M, et al. DSM-IV mania symptoms in a prepubertal and early adolescent bipolar disorder phenotype compared to attention-deficit hyperactive and normal controls. J Child Adolesc Psychopharmacol 2002;12:11-25
43. Coyle JT, Pine DS, Charney DS, et al. Depression and bipolar support alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in children and adolescents. J Am Acad Child Adolesc Psychiatry 2003;42:1494-1503
44. Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 1998;37:171-178
45. Fristad MA, Gavazzi SM, Mackinaw-Koons B. Family psychoeducation: an adjunctive intervention for children with bipolar disorder. Biol Psychiatry 2003;53:1000-1008
46. Balant-Gorgia AE, Eisele R, Balant L, et al. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Eur Arch Psychiatry Neurol Sci 1984;234:1-4
47. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord 1980;2:279-288
48. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999;14:339-343
49. Ghaemi SN, Goodwin FK. Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. J Clin Psychopharmacol 1999;19:354-361
50. Lyseng-Williamson KA, Perry CM. Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs 2004;18:367-376
51. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161:169-171
52. Fuchs DC. Clozapine treatment of bipolar disorder in a young adolescent. J Am Acad Child Adolesc Psychiatry 1994;33:1299-1302
53. Kowatch RA, Suppes T, Gilfillan SK, et al. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: a clinical case series. J Child Adolesc Psychopharmacol 1995;5:241-253
54. Masi G, Mucci M, Millepiedi S. Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 2002;12:93-99
55. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-1154
56. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004;161:1057-1065
57. Frazier JA, Meyer MC, Biederman J, et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 1999;38:960-965
58. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-1226
59. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841-849
60. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
61. Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62:273-281
62. Soutullo CA, Sorter MT, Foster KD, et al. Olanzapine in the treatment of adolescent acute mania: a report of seven cases. J Affect Disord 1999;53:279-283
63. Frazier JA, Biederman J, Tohen M, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001;11:239-250
64. Catapano-Friedman L. Effectiveness of quetiapine in the management of psychotic depression in an adolescent boy with bipolar disorder, mixed, with psychosis [letter]. J Child Adolesc Psychopharmacol 2001;11:205-206
65. Schaller JL, Behar D. Quetiapine for refractory mania in a child [letter]. J Am Acad Child Adolesc Psychiatry 1999;38:498-499
66. DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002;41:1216-1223
67. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748
68. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658
69. Patel NC, Sierk P, Dorson PG, et al. Experience with ziprasidone [letter]. J Am Acad Child Adolesc Psychiatry 2002;41:495
70. TEAM Study. Treatment of Early Age Mania. Available at: http://www.clinicaltrials.gov/ct/gui/show/ NCI00057681;jsessionid= 604FB8D0FB74B4249CC2F11E812F188E?order=3. Accessed April 8, 2004
71. Steiner H, Saxena K, Chang K. Psychopharmacologic strategies for the treatment of aggression in juveniles. CNS Spectr 2003;8:298-308
72. Connor DF. Aggression and Anti-Social Behavior in Children and Adolescents. Research and Treatment. New York, NY: The Guilford Press; 2002
73. Schur SB, Sikich L, Findling RL, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), pt 1: a review. J Am Acad Child Adolesc Psychiatry 2003;42:132-144
74. Connor DF, Ozbayrak KR, Kusiak KA, et al. Combined pharmacotherapy in children and adolescents in a residential treatment center. J Am Acad Child Adolesc Psychiatry 1997;36:248-254
75. Weller EB, Rowan A, Elia J, et al. Aggressive behavior in patients with attention-deficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. J Clin Psychiatry 1999;60(suppl 15):5-11
76. Heyneman EK. The aggressive child. Child Adolesc Psychiatr Clin N Am 2003;12:667-677
77. Pappadopulos E, MacIntyre JC II, Crismon ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY), pt 2. J Am Acad Child Adolesc Psychiatry 2003;42:145-161
78. Pappadopulos E, Jensen PS, Schur SB, et al. "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 2002;28:111-121
79. Anderson LT, Campbell M, Adams P, et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989;19:227-239
80. Anderson LT, Campbell M, Grega DM, et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984;141:1195-1202
81. Perry R, Campbell M, Adams P, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989;28:87-92
82. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347: 314-321
83. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114:e634-e641. Epub 2004 Oct 18
84. Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003;42:1443-1450
85. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997;33:155-159
86. Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996;6:177-190
87. Gagliano A, Germano E, Pustorino G, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 2004;14:39-47
88. Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 2002;41:140-147
89. Masi G, Cosenza A, Mucci M, et al. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003;64:1039-1047
90. Masi G, Cosenza A, Mucci M, et al. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001;40:1206-1214
91. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36:685-693
92. Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998;37:372-376
93. Perry R, Pataki C, Munoz-Silva DM, et al. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 1997;7:167-179
94. Zuddas A, Di Martino A, Muglia P, et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000;10:79-90
95. Kemner C, Willemsen-Swinkels SH, de Jonge M, et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002;22:455-460
96. Malone RP, Cater J, Sheikh RM, et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001;40:887-894
97. Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44
98. Stavrakaki C, Antochi R, Emery PC. Olanzapine in the treatment of pervasive developmental disorders: a case series analysis. J Psychiatry Neurosci 2004;29:57-60
99. Corson AH, Barkenbus JE, Posey DJ, et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004;65:1531-1536
100. Findling RL, McNamara NK, Gracious BL, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004; 14:287-294
101. Martin A, Koenig K, Scahill L, et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999;9:99-107
102. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41:921-927
103. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:455-463
104. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000;39:15-25
105. Mukaddes NM, Abali O, Gurkan K. Short-term efficacy and safety of risperidone in young children with autistic disorder (AD). World J Biol Psychiatry 2004;5:211-214
106. Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997;54:1073-1080
107. Campbell M, Kafantaris V, Cueva JE. An update on the use of lithium carbonate in aggressive children and adolescents with conduct disorder. Psychopharmacol Bull 1995;31:93-102
108. Campbell M, Adams PCB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995;34:445-453
109. Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984;41:650-656
110. Cueva JE, Overall JE, Small AM, et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996;35:480-490
111. Malone RP, Delaney MA, Luebbert JF, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000;57:649-654
112. Steiner H, Petersen ML, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. J Clin Psychiatry 2003;64:1183-1191
113. Findling RL, Blumer JL, Kauffman R, et al. Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder [poster]. Presented at the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; June 20-24, 2004; Paris, France
114. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000;39:509-516
115. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159: 1337-1346
116. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001;62:239-248
117. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41:1026-1036
118. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001;11:5-13
119. Buitelaar JK. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 2000;10:19-26
120. Croonenberghs J, Fegert JM, Findling RL, et al. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005;44:64-72
121. Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004;161:677-684
122. Turgay A, Binder C, Snyder R, et al. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002;110:e34
123. Frazier JA, Cohen LG, Jacobsen L, et al. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol 2003;23:87-91
124. Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000;20:220-225
125. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983;40:1113-1117
126. Aguilar EJ, Keshavan MS, Martinez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994;151:1819-1821
127. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544
128. Wadenberg ML, Soliman A, VanderSpek SC, et al. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001;25:633-641
129. Seeman P, Bzowej NH, Guan HC, et al. Human brain dopamine receptors in children and aging adults. Synapse 1987;1:399-404
130. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998;43:596-604
131. Theisen FM, Linden A, Geller F, et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res 2001;35: 339-345
132. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 2004;24:429-436
133. Martin A, Landau J, Leebens P, et al. Risperidone-associated weight gain in children and adolescents: retrospective chart review. J Child Adolesc Psychopharmacol 2000;10:259-268
134. Menza M, Vreeland B, Minsky S, et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004;65:471-477
135. Vreeland B, Minsky S, Menza M, et al. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003;54: 1155-1157
136. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002;63(suppl 4):56-62
137. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequences. Br J Psychiatry 2003;182:199-204
138. Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999;9:239-245
139. Becker D, Liver O, Mester R, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003;64:761-766
140. Dunbar F, Kusumakar V, Daneman D, et al. Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 2004; 161:918-920
141. Giles TD, Modlin RK. Death associated with ventricular arrhythmia and thioridazine hydrochloride. JAMA 1968;205:108-110
142. Goodson WH Jr, Litkenhous EE Jr. Sudden unexplained death in a psychiatric patient taking thioridazine. South Med J 1976;69:311,315,320
143. Blair J, Scahill L, State M, et al. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005;44:73-79
144. Aubry J-M, Simon AE, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J Clin Psychiatry 2000;61:649-655
145. Larson MF, Hauser A. Possible ziprasidone-induced mania [letter]. J Am Acad Child Adolesc Psychiatry 2003;42:1012
146. Rachid F, Bertschy G, Bondolfi G, et al. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 2004;65:1537-1545
147. Lane H-Y, Lin Y-C, Chang W-H. Mania induced by risperidone: dose related? [letter] J Clin Psychiatry 1998;59:85-86
148. Lindenmayer J-P, Klebanov R. Olanzapine-induced manic-like syndrome [letter]. J Clin Psychiatry 1998;59:318-319
149. Schnierow BJ, Graeber DA. Manic symptoms associated with initiation of risperidone [letter]. Am J Psychiatry 1996;153:1235-1236
150. London JA. Mania associated with olanzapine [letter]. J Am Acad Child Adolesc Psychiatry 1998;37:135-136